“…The disease can be localized or systemic and is classified according to the identity of the amyloid fibril-forming protein [1]. Once the presence of amyloidosis is confirmed in a tissue biopsy specimen, it is critical to identify the amyloid type accurately, as management differs substantially depending on the nature and source of the amyloid-forming protein, ranging from supportive care through to aggressive chemotherapy or organ transplantation [2]. With a new era of amyloid therapeutics upon us, such as antisense therapies, transthyretin stabilizers, and anti-amyloid fibril antibodies [3], accurate diagnosis has become more important than ever.…”